Photograph by Kimberly White — Getty Images for Vanity Fair 23andMe is now worth more than $1 billion, as it begins tapping its massive DNA database to make new drugs.
Genetic analytics company 23andMe last week reported via a regulatory filing that it had raised $79 million in a Series E venture capital round that could eventually hit $150 million. Market research firm VC Experts subsequently pulled Delaware filings that show the round was done at a post-money valuation of approximately $1.03 billion (based on the $79m, not the $150m).
via fortune.com
Recent Comments